抄録
To evaluate the loading regimen of teicoplanin, the total concentration of teicoplanin (C24) and free teicoplanin concentrations (C24free) in serum were measured 24 hrs after the start of therapy.
Thirty-eight points of blood samples from 35 patients were obtained after the intravenous loading of teicoplanin (200 or 400 mg per dose, every 12 hrs). Twelve patients received 200 mg of teicoplanin twice a day with a loading time interval of 12 hrs (400 mg/day group), and others received 400 mg twice a day, every 12 hrs (800 mg/day group). The acquired C24 was 4.4±1.7μg/mL (mean±SD) in the 400 mg/day group and 8.9±3.7μJug/mL in the 800 mg/day group.C24free was 0.7±0.17μg/mL in the 400 mg group and 1.3±0.17 μg/mL in the 800 mg group.C24 and C24free showed large variations among patients, and most of them remained at inadequate levels for the therapy when C24>10, μg/mL or C24free>1.56, μg/mL were set asthe target ranges. C24free was well correlated with the body weight-adjusted loading dose (y=0.075x, r2=0.85). Although, C24 showed a weak correlation (y=0.505x, r2= 0.28). This result was not affected by the renal function.
Therefore, it is suggested that for the clinical dosing schedules of teicoplanin, loading 10 mg/kg twice a day every 12 hrs should be an adequate amount for a loading dose. In addition, a maintenance dose, with the amount modulated according to the renal function of each patient, should be administered when necessary.
